Viva Biotech Holdings (VB0) — Capital Reinvestment Ratio
Latest as of June 2023:
0.32x
Viva Biotech Holdings (VB0) has a Capital Reinvestment Ratio of 0.32x as of June 2023, meaning it reinvests 0% of its operating cash flow (€158.72 Million) in capital expenditures (€50.80 Million). See Viva Biotech Holdings (VB0) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.32x
Capex / Operating Cash Flow
Operating Cash Flow
€158.72 Million
EUR
Capital Expenditures
€50.80 Million
EUR
Data as of
Jun 2023
Most recent filing
Viva Biotech Holdings Capital Reinvestment Ratio (2016–2024)
This chart tracks Viva Biotech Holdings's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for Viva Biotech Holdings (2016–2024)
Year-by-year Capital Reinvestment Ratio for Viva Biotech Holdings from 2016 to 2024. For live market cap and broader valuation context, see Viva Biotech Holdings stock valuation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.51x | €373.99 Million | €191.67 Million | ▲ +4.6% |
| 2023 | 0.49x | €383.40 Million | €187.84 Million | ▼ -24.1% |
| 2022 | 0.65x | €386.05 Million | €249.33 Million | ▼ -91.1% |
| 2021 | 7.26x | €77.83 Million | €565.18 Million | ▼ -47.1% |
| 2020 | 13.72x | €43.18 Million | €592.62 Million | ▲ +1023.9% |
| 2019 | 1.22x | €46.01 Million | €56.19 Million | ▼ -68.5% |
| 2018 | 3.87x | €12.11 Million | €46.90 Million | ▲ +470.9% |
| 2017 | 0.68x | €27.89 Million | €18.92 Million | ▲ +95.2% |
| 2016 | 0.35x | €21.12 Million | €7.34 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow